[go: up one dir, main page]

SE9603305D0 - New picornaviruses, vaccines and diagnostic kits - Google Patents

New picornaviruses, vaccines and diagnostic kits

Info

Publication number
SE9603305D0
SE9603305D0 SE9603305A SE9603305A SE9603305D0 SE 9603305 D0 SE9603305 D0 SE 9603305D0 SE 9603305 A SE9603305 A SE 9603305A SE 9603305 A SE9603305 A SE 9603305A SE 9603305 D0 SE9603305 D0 SE 9603305D0
Authority
SE
Sweden
Prior art keywords
picornaviruses
protein
vaccines
seq
diagnostic kits
Prior art date
Application number
SE9603305A
Other languages
English (en)
Swedish (sv)
Inventor
Bo Niklasson
Original Assignee
Bo Niklasson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bo Niklasson filed Critical Bo Niklasson
Priority to SE9603305A priority Critical patent/SE9603305D0/xx
Publication of SE9603305D0 publication Critical patent/SE9603305D0/xx
Priority to JP51356498A priority patent/JP4440345B2/ja
Priority to AT97939321T priority patent/ATE278709T1/de
Priority to ES97939321T priority patent/ES2229386T3/es
Priority to EP97939321A priority patent/EP0941240B1/fr
Priority to AU41435/97A priority patent/AU4143597A/en
Priority to DE69731106T priority patent/DE69731106T2/de
Priority to PCT/SE1997/001515 priority patent/WO1998011133A1/fr
Priority to EA199900286A priority patent/EA199900286A1/ru
Priority to US09/147,801 priority patent/US7101554B2/en
Priority to US11/448,321 priority patent/US20070003573A1/en
Priority to US11/477,709 priority patent/US7855277B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/085Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
SE9603305A 1996-09-11 1996-09-11 New picornaviruses, vaccines and diagnostic kits SE9603305D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE9603305A SE9603305D0 (sv) 1996-09-11 1996-09-11 New picornaviruses, vaccines and diagnostic kits
US09/147,801 US7101554B2 (en) 1996-09-11 1997-09-09 Picornaviruses, vaccines and diagnostic kits
EP97939321A EP0941240B1 (fr) 1996-09-11 1997-09-09 Nouveaux picornavirus, vaccins et trousses de diagnostic
AT97939321T ATE278709T1 (de) 1996-09-11 1997-09-09 Neue pikcornaviren, impfstoffe und diagnostische kits
ES97939321T ES2229386T3 (es) 1996-09-11 1997-09-09 Nuevos piconavirus, vacunas y kits diagnosticos.
JP51356498A JP4440345B2 (ja) 1996-09-11 1997-09-09 新規なピコルナウイルス、ワクチンおよび診断薬キット
AU41435/97A AU4143597A (en) 1996-09-11 1997-09-09 New picornaviruses, vaccines and diagnostic kits
DE69731106T DE69731106T2 (de) 1996-09-11 1997-09-09 Neue pikcornaviren, impfstoffe und diagnostische kits
PCT/SE1997/001515 WO1998011133A1 (fr) 1996-09-11 1997-09-09 Nouveaux picornavirus, vaccins et trousses de diagnostic
EA199900286A EA199900286A1 (ru) 1996-09-11 1997-09-09 Новые пикорнавирусы, вакцины и диагностические наборы
US11/448,321 US20070003573A1 (en) 1996-09-11 2006-06-07 Picornaviruses, vaccines and diagnostic kits
US11/477,709 US7855277B2 (en) 1996-09-11 2006-06-29 Picornaviruses, vaccines and diagnostic kits

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9603305A SE9603305D0 (sv) 1996-09-11 1996-09-11 New picornaviruses, vaccines and diagnostic kits

Publications (1)

Publication Number Publication Date
SE9603305D0 true SE9603305D0 (sv) 1996-09-11

Family

ID=20403847

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9603305A SE9603305D0 (sv) 1996-09-11 1996-09-11 New picornaviruses, vaccines and diagnostic kits

Country Status (10)

Country Link
US (3) US7101554B2 (fr)
EP (1) EP0941240B1 (fr)
JP (1) JP4440345B2 (fr)
AT (1) ATE278709T1 (fr)
AU (1) AU4143597A (fr)
DE (1) DE69731106T2 (fr)
EA (1) EA199900286A1 (fr)
ES (1) ES2229386T3 (fr)
SE (1) SE9603305D0 (fr)
WO (1) WO1998011133A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9603305D0 (sv) * 1996-09-11 1996-09-11 Bo Niklasson New picornaviruses, vaccines and diagnostic kits
GB0120437D0 (en) * 2001-08-22 2001-10-17 Nya Apodemus Ab Diabetic model
AU2003228072A1 (en) * 2002-04-23 2003-11-10 Susanne Johansson A new family of picornaviruses
WO2004073710A1 (fr) * 2003-02-21 2004-09-02 Apodemus Ab Methode de traitement a l'aide de pleconaril de maladies induites par le virus ljungan
AU2006343645B2 (en) * 2006-05-01 2011-12-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Methods and agents for detecting Parechovirus
US8326439B2 (en) * 2008-04-16 2012-12-04 Nevro Corporation Treatment devices with delivery-activated inflatable members, and associated systems and methods for treating the spinal cord and other tissues
US20130071421A1 (en) * 2009-10-02 2013-03-21 W. Ian Lipkin Turkey viral hepatitis virus and uses thereof
US9572528B1 (en) 2012-08-06 2017-02-21 Los Angeles Biomedical Research Insitute at Harbor-UCLA Medical Center Monitor for SIDS research and prevention

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229111A (en) 1991-01-31 1993-07-20 Wiscosnin Alumni Research Foundation Method of inhibiting picornavirus disease
SE9603305D0 (sv) * 1996-09-11 1996-09-11 Bo Niklasson New picornaviruses, vaccines and diagnostic kits

Also Published As

Publication number Publication date
US7101554B2 (en) 2006-09-05
US20070003574A1 (en) 2007-01-04
DE69731106D1 (de) 2004-11-11
EP0941240B1 (fr) 2004-10-06
JP4440345B2 (ja) 2010-03-24
EA199900286A1 (ru) 2000-04-24
US20070003573A1 (en) 2007-01-04
EP0941240A1 (fr) 1999-09-15
US7855277B2 (en) 2010-12-21
ES2229386T3 (es) 2005-04-16
JP2001500503A (ja) 2001-01-16
US20030044960A1 (en) 2003-03-06
AU4143597A (en) 1998-04-02
WO1998011133A1 (fr) 1998-03-19
DE69731106T2 (de) 2006-02-23
ATE278709T1 (de) 2004-10-15

Similar Documents

Publication Publication Date Title
Tufan et al. COVID-19, immune system response, hyperinflammation and repurposingantirheumatic drugs
Webby et al. Protection and compensation in the influenza virus-specific CD8+ T cell response
US6811780B2 (en) Methods of using cytokine antagonists to treat HIV infection and AIDS
Kirchberger et al. Modulation of the immune system by human rhinoviruses
CA3167493A1 (fr) Epitopes de lymphocytes t et compositions associees utiles dans la prevention, le diagnostic et le traitement de la covid-19
Rossi et al. Respiratory syncytial virus–Host interaction in the pathogenesis of bronchiolitis and its impact on respiratory morbidity in later life
EP2201035B1 (fr) Nouvelles cytokines aviaires et séquences génétiques codant ces dernières
US7371525B2 (en) Compositions and methods for diagnosing and treating severe acute respiratory syndrome (SARS)
Meurs et al. The interferon inducing pathways and the hepatitis C virus
WO2001062287A1 (fr) Methodes de prevention et traitement de l'asthme et d'etats allergiques
SE9603305D0 (sv) New picornaviruses, vaccines and diagnostic kits
Yang et al. Lung type II alveolar epithelial cells collaborate with CCR2+ inflammatory monocytes in host defense against poxvirus infection
US5622861A (en) Recombinant DNA encoding hepatitis A virus receptor
Gorham et al. Genetic control of interleukin 12 responsiveness: implications for disease pathogenesis
Lim et al. Potentiation of antigen‐specific, Th1 immune responses by multiple DNA vaccination with an ovalbumin/interferon‐γ hybrid construct
Petro Disparate expression of IL-12 by SJL/J and B10. S macrophages during Theiler’s virus infection is associated with activity of TLR7 and mitogen-activated protein kinases
Zonaro et al. Differential pattern of sequence heterogeneity in the hepatitis C virus E1 and E2/NS1 proteins
Weiss et al. Pathogenesis of murine coronavirus infection
US20230079898A1 (en) Compositions and methods for treating and preventing hepatitis b and d
Minami et al. A NOVEL SENSITIVE METHOD FOR THE DETECTION OF LAMIVU-DINE-RESISTANT HBV MUTANTS USING PEPTIDE NUCLEIC ACIDS-MEDIATED PCR CLAMPING AND RESTRICTION FRAGMENT LENGTH
US20240301082A1 (en) Anti-cd73 compounds to treat oncovirus-positive cancers
CN104780918A (zh) 用于预防和/或治疗丙型肝炎的氮杂环丁酮化合物及其组合物
Brown et al. Racial differences in response to interferon and ribavarin+/-ketoprofen in patients with chronic hepatitis C who have previously failed interferon monotherapy
Sinha et al. Cost-effectiveness of interferon based management strategies in children with chronic hepatitis C virus (HCV) infection
Kim et al. Analysis of the envelope region of hepatitis G virus isolated from Korean patients